View Older Stories View More Recent Stories
-
Eli Lilly & Co. (LLY) Tops Q2 EPS by 72c; lifts guidance
-
Stocks expected to have increasing option volume: LLY BDX DDOG WBD QSR PODD RL ZBH H CELH ELAN CROX YETI WRBY PTON
-
Eli Lilly Q2 earnings preview: analysts eye obesity drug sales momentum
-
Eli Lilly & Co. (LLY) call put ratio 1 call to 1 put into quarter results
-
Eli Lilly & Co. (LLY) call put ratio 2.2 calls to 1 put into quarter results
-
Bernstein on Eli Lilly (LLY): 'We've Been Waiting for This'
-
Novo Nordisk (NVO) stock: Where next after profit warning?
-
Trump admin to pilot coverage of weight‑loss drugs under Medicare and Medicaid - WaPo
-
White House: Trump took action on pharma Thursday, sent letters to CEOs
-
White House: calls on Eli Lilly to take actions within 60 days
-
Lilly stock falls as Mounjaro fails to show superiority over Trulicity
-
Lilly's Mounjaro shows cardiovascular protection in head-to-head trial
-
Deutsche Bank defends Eli Lilly (LLY) on Novo-related sell-off
-
Eli Lilly (LLY) PT Raised to $920 at BMO Capital
-
Hims & Hers (HIMS) reportedly makes statement on congressional letter to FDA
-
Hims & Hers Health, Inc. (NYSE: HIMS) Falls, Group Of 81 Bipartisan Lawmakers Sign Letter On Glp-1 Action
-
Lilly completes Verve Therapeutics acquisition for cardiovascular treatments
-
Eli Lilly receives positive opinion for donanemab in Europe
-
Lilly tender offer for Verve expires with 55.7% of shares tendered
-
BMO Capital on Eli Lilly (LLY): 'ALZ 3 Interim Could Read Positively in Near Future'
-
15 names that Morgan Stanley’s analysts expect to move meaningfully on earnings
-
Eli Lilly (LLY) PT Raised to $942 at Guggenheim
-
FDA approves updated dosing for Lilly's Kisunla Alzheimer's treatment
-
Eli Lilly & Co. (LLY) call put ratio 9.5 calls to 1 put with a focus on a spreader of July 850, and 960 calls
-
JPMorgan Reiterates Overweight Rating on Eli Lilly (LLY)
-
Morgan Stanley on Compounder Lawsuits: 'experts think the courts would likely refuse to dismiss the case and that it could take 2-3 years to resolve'
-
RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimer’s market
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
BMO Capital Downgrades Verve Therapeutics (VERV) to Market Perform
-
Eli Lilly & Co. (LLY) announced FDA approval of updated label for Lilly’s Amyvid (florbetapir F 18 injection) to support diagnosis of Alzheimer’s disease in patients
-
Chardan Comments on iBio, Inc. (IBIO)
-
Citi bullish on Lilly as Orforglipron unlocks $40B+ obesity market
-
Citi Reiterates Buy Rating on Eli Lilly (LLY)
-
BMO Capital on Eli Lilly (LLY): 'Is It Time to BELIEVE?'
-
Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) Declares $1.50 Quarterly Dividend; 0.8% Yield
-
Evercore ISI Reiterates In Line Rating on Eli Lilly (LLY)
-
BMO Capital: 'Eli Lilly (LLY) Metabolic Portfolio Shows New Legs at ADA Event'
-
Truist Reiterates Buy Rating on Eli Lilly (LLY) Following OFG Presentation at ADA
-
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY)
-
GLP-1s Should Be First Line To Prevent Heart Disease, Acc Says - Bloomberg
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
Eli Lilly (LLY) to Acquire VERV; Bernstein: 'We Like the Deal'
-
Eli Lilly and Verve's gene-editing M&A deal 'an important milestone' - Citizens JMP
-
Eli Lilly & Co. (LLY) to acquire Verve Therapeutics (VERV) for $10.50/sh Cash plus CVR
-
Eli Lilly & Co. (LLY) In Advanced Talks To Buy Verve For Up To $1.3bln- FT
-
Bernstein: 'Zepbound Continues to Propel Eli Lilly (LLY)'
-
Eli Lilly & Co. (LLY) to offer all approved doses of Zepbound single-dose vials through LillyDirect Self Pay Pharmacy Solutions
-
Jefferies: 'We highlight multiple de-risked or commercial-stage names that we think have promising M&A potential'
-
Bernstein Reiterates Outperform Rating on Eli Lilly (LLY) Ahead of ADA 2025
